Kyprolis (carfilzomib)

Kyprolis (carfilzomib) is a prescription medication used to treat multiple myeloma, a type of blood cancer affecting plasma cells. It works by blocking proteasomes, which are protein structures in cells that help break down unneeded or damaged proteins. By inhibiting proteasomes, Kyprolis causes an accumulation of these proteins in cancer cells, leading to their death. It is typically given in combination with other treatments and is administered intravenously. Kyprolis is designed to target and kill cancer cells selectively, helping to control the progression of multiple myeloma and improve patients' quality of life.